Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

BofA Securities maintained an Underperform rating on shares of Hims & Hers Health, Inc. (NYSE:HIMS) with a steady price ...

These medications were sitagliptin, liraglutide, glimepiride, or insulin glargine U-100. Sitagliptin, liraglutide, and ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...

Ke, X. and Ma, T. (2025) Protective Effect of Liraglutide on Early Renal Fibrosis in Diabetes Mice. Journal of Biosciences and Medicines, 13, 84-91. doi: 10.4236/jbm.2025.131008 .

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.